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We previously demonstrated that oral supplementation with antioxidants induced hyperactivity of 2 
hypothalamus-pituitary-adrenal (HPA axis), attested by hypercorticoidism, through an up-regulation 3 
of adrenocorticotrophic hormone (ACTH) receptors (MC2R) in adrenal. This study analyzed the role 4 
of peroxisome proliferator-activated receptor (PPAR)-γ on HPA axis hyperactivity induced by N-5 
acetyl-cysteine (NAC). Male Swiss-Webster mice were orally treated with NAC for 1, 3, 5, 10, 15, or 6 
18 consecutive days. The PPAR-γ agonist rosiglitazone and/or antagonist GW9662 were daily-7 
injected i.p. for 5 consecutive days, starting concomitantly with NAC treatment. Rosiglitazone 8 
treatment inhibited NAC-induced adrenal hypertrophy and hypercorticoidism. Rosiglitazone also 9 
significantly reversed the NAC-induced increase in the MC2R expression in adrenal, but not 10 
steroidogenic acute regulatory protein (StAR). NAC treatment reduces the expression of PPARγ in 11 
the adrenals, but rosiglitazone did not restore the expression of this cytoprotective gene. In addition, 12 
GW9662 blocked the ability of rosiglitazone to decrease plasma corticosterone levels in NAC-treated 13 
mice. In conclusion, our findings showed that antioxidant supplementation induced a state of 14 
hypercorticoidism through down-regulation of PPARγ expression in the adrenals, in a mechanism 15 
probably related to a down-regulation of ACTH receptor expression. 16 
 17 











Reactive oxygen species (ROS) are the initial species generated by oxygen reduction, 2 
including superoxide, hydroxyl radical, and hydrogen peroxide [1]. Under physiological conditions, 3 
endogenous antioxidant enzymes regulate the overproducti n of ROS to prevent undesirable 4 
functional collateral damage [2]. The excessive production of ROS occurs when there is an imbalance 5 
between cellular antioxidant defense systems and the endogenous or exogenous pro-oxidant burden, 6 
leading to DNA cleavage, protein oxidation, and lipid eroxidation, ultimately resulting in cellular 7 
dysfunction and apoptosis [3,4]. Despite this, exist nt evidence highlights the beneficial role of 8 
superoxide and hydrogen peroxide in the maintenance of cellular redox homeostasis acting as 9 
signaling molecules in a physiological process. Accordingly, the release of reduced amounts of 10 
oxidants from the mitochondria or other sources can activate a defensive response that appears to 11 
protect the organism from subsequent higher stresses[5–7]. Thereat, the growth of indiscriminate 12 
consume of supplements with antioxidants to combat diseases associated with aging by the general 13 
people [8,9] can culminate in cellular stress affecting most diverse systems of the body.  14 
Indeed, we previously showed that prolonged treatmen  with two different antioxidants, 15 
vitamin E and N-acetylcysteine (NAC), induced a rise in the circulating glucocorticoid levels in rats 16 
by a mechanism related to increased expression of both adrenocorticotrophic hormone (ACTH) 17 
receptor, known as MC2R, and steroidogenic acute regulatory protein (StAR) in the adrenal gland 18 
[10].  Peroxisome proliferator-activated receptor (PPAR)γ is an isoform of the PPAR subset of 19 
nuclear receptors, which activate the expression of their target genes by binding to peroxisome 20 
proliferator response elements (PPREs) [11]. The PPREs are found in genes that control the 21 
expression of endogenous antioxidant enzymes, including SOD, catalase, and heme oxygenase-1, and 22 
the activation of PPARγ induces a transactivation of these genes [12–14]. In addition, we 23 
demonstrated that the reduction of PPARγ expression in adrenals is directly associated withthe high 24 
expression of MC2R in these glands as so as hypercorticoidism noted in animals with diabetes [15]. 25 
Thus, NAC-induced hyperactivation of the adrenal cortex could be associated with the interference of 26 
 4 
signaling pathways mediated by PPARγ. In this study, we evaluated the contribution of the PPARγ to 1 
the NAC-induced hypercorticoidism in healthy mice, using a synthetic PPARγ agonist rosiglitazone. 2 
 3 
MATERIALS AND METHODS 4 
Chemicals 5 
Dimethyl sulfoxide (DMSO) was purchased from Sigma Chemical Co. (Saint Louis, MO, USA), 6 
rosiglitazone and GW9662 from Cayman Chemicals (Saint Louis, MO, USA), ethanol, methanol and 7 
xylene from Merck (Rio de Janeiro, Brazil) and sodium heparin from Roche (São Paulo, Brazil). All 8 
solutions were freshly prepared immediately before us . 9 
Animals 10 
In accordance with the guidelines of the Committee on Use of Laboratory Animals of 11 
Oswaldo Cruz Institute (CEUA-IOC/Fiocruz, license L-027/2016), male Swiss-Webster mice 12 
obtained from Oswaldo Cruz Foundation breeding colony were used. Mice were housed in groups of 13 
four in temperature-, humidity-, and light-controlled (12 h light: 12 h darkness cycle) colony room. 14 
Mice were given access ad libitum to food and water. 15 
Treatments 16 
Forty-two male mice were randomly assigned into 6 experimental groups as follows: control 17 
mice (n = 7); NAC-treated mice for 1 day (n = 7); NAC-treated mice for 3 days (n = 7); NAC-treated 18 
mice for 5 days (n = 7); NAC-treated mice for 10 days (n = 7); NAC-treated mice for 15 days (n = 7); 19 
NAC-treated mice for 18 days (n = 7). In another setting of experiments, 28 male mice were randomly 20 
divided into 4 experimental groups: control mice (n = 7); rosiglitazone-treated mice (n = 7); NAC-21 
treated mice (n = 7); mice treated with NAC plus rosiglitazone (n = 7). In a third setting of 22 
experiments, 30 male mice were randomly assigned into 5 experimental groups as follows: control 23 
mice (n = 6); NAC-treated mice (n = 6); mice treated with NAC plus rosiglitazone (n = 6); mice 24 
 5 
treated with NAC plus GW9662 (n = 6); mice treated with NAC plus rosiglitazone plus GW9662 (n = 1 
6).  2 
The mice were treated with antioxidant NAC (150 mg/kg body weight) [10] by gavage once a 3 
day, during 1, 3, 5, 10, 15, or 18 consecutive days. Control mice received an equal volume of vehicle 4 
(sterile saline 0.9%). In some experiments, the mice were treated concomitantly with NAC (150 5 
mg/kg body weight), PPARγ agonist rosiglitazone (0.5 mg/kg, i.p.), and/or PPARγ antagonist 6 
GW9662 (0.5 mg/kg, i.p.) [16] daily for 5 consecutive days. Untreated mice received an equal volume 7 
of vehicle (DMSO 0.1%, i.p.). All analyzes were performed 24h after last treatment with NAC.  8 
Determination of micro and macroscopic adrenal hypertrophy indexes 9 
 Adrenal glands were quickly removed from mice and cleaned of surrounding fat in ice. 10 
Instantly after dissection, the adrenal glands were fixed in Milloning fixative solution for 24h and, 11 
then, embedded in paraffin. Paraffin-embedded sections of 3 μm were deparaffinized with xylene, 12 
rehydrated by a graded series of ethanol washes, and st ined with hematoxylin and eosin (H&E). The 13 
tissue sections were mounted in aqueous medium and images digitized via scanner microscope 14 
(Pannoramic SCAN150, 3D Histech, Budapest, Hungary) using a 20x objective lens. Images obtained 15 
from the zona fasciculata of the adrenal cortex were analyzed with Image Pro lus 6.2 software 16 
(Media Cybernetics, Rockville, MD, USA) to determine the mean area of cells. We analyzed at least 17 
ten different fields from zona fasciculata of each adrenal gland section. To assess adrenal gland 18 
hypertrophy macroscopically, the ratio between adrenal weight and body weight was determined. 19 
Evaluation of mRNA expression of MC2R, PPARγ, and StAR by real-time PCR  20 
 Total RNA was isolated from adrenal glands using TRI Reagent® and reverse-transcribed to 21 
cDNA using the RevertAid Reverse Transcriptase (Thermo Fisher Scientific, Waltham, MA, USA). 22 
Real-time PCR was performed with the StepOnePlus Real Time PCR System (Applied Biosystems, 23 
Foster City, CA, USA) using a Mix (5x HOT FIREPol® EvaGreen® qPCR Mix Plus (ROX); Solis 24 
BioDyne, Tartu, Estonia) according to the manufacturer’s instructions. The amplification program 25 
included an initial activation step at 95ºC for 15min, followed by denaturation at 95ºC for 15s, 26 
 6 
annealing between 59º-62ºC and finally elongation at 72ºC for 20s, for 40 cycles. Fluorescence was 1 
measured after each extension step, and the specificity of amplification was evaluated by melting 2 
curve analysis. The house-keeping gene GADPH was used a  a control to normalize RNA samples. 3 
Relative gene expression levels were calculated using a standard curve for each gene. Amplification 4 
efficiencies were identical or similar between genes of interest and controls. Primers (Table 1) and 5 
probes were designed in our laboratory and purchased from Eurofins Genomics (Louisville, KY, 6 
USA) or Invitrogen (Carlsbad, CA, USA). 7 
 8 
Table 1: Primer sequences used for RT-qPCR 9 













Corticosterone quantification 11 
Mice were euthanized (ketamine 140 mg/Kg and xylazine 20 mg/Kg i.p.), during the nadir 12 
(08:00 h) of the circadian rhythm as described previously [17], and blood was immediately collected 13 
from abdominal aorta using heparin (40 U/ml) for coti sterone quantification. Plasma was obtained 14 
after sample centrifugation for 10 min at 1,000 × g and stored at -20°C until use. Plasma 15 
corticosterone levels were quantified by radioimmunoassay or ELISA, following manufacturer's 16 
 7 
guidelines (MP Biomedicals, Solon, USA, and Cayman Chemicals, Ann Arbor, MI, USA, 1 
respectively). 2 
Statistical analysis 3 
Data are reported as mean ± Standard Error of the Mean (S.E.M.). The data were evaluated to 4 
ensure normal distribution and statistically analyzed by one-way ANOVA followed by a Student-5 
Newman–Keuls post-hoc test. In the case of real-time PCR, the data were assessed by non-parametric 6 
test Kruskall-Wallis followed by U de Mann Whitney. Probability values (p) of 0.05 or less were 7 
considered significant.  8 
 9 
RESULTS 10 
NAC increases plasma corticosterone levels in Swiss-Webster mice  11 
We observed that NAC induced an increase in the circulating levels of corticosterone when 12 
used for 3, 5, 10, 15, or 18 consecutive days compared to controls, however, a single administration of 13 
the antioxidant was unable to significantly alter circulating hormone levels (Figure 1). Based on these 14 
data, we chose the scheme of 5-day NAC treatment to evaluate the role of the nuclear receptor PPARγ 15 
on antioxidant-induced hypercorticoidism. 16 
 17 
 8 
Figure 1: Kinetics of NAC-induced hypercorticoidism in mice. NAC (150 mg/kg, oral route) and 1 
was given daily for 1, 3, 5, 10, 15 or 18 consecutive days. Untreated animals received an equal 2 
amount of vehicle (0.9% saline). Data are expressed as the mean ± SEM. This result is a 3 
representative of two independent assays. ++p < 0 01 compared to control mice. 4 
 5 
Rosiglitazone reduces adrenal hypertrophy and hypercorticoidism induced by NAC treatment 6 
 NAC-induced adrenal hypertrophy as evidenced by an increase in the mean area of cells in 7 
zona fasciculata of adrenal cortex (Figures 2C and 2E) and in the ratio between adrenal and body 8 
weight (Figure 2F) compared to untreated mice (Figures 2A, 2E, and 2F). Remarkably, all of these 9 
changes were clearly sensitive to rosiglitazone treatm nt (Figures 2D, 2E, and 2F), as evidenced by 10 
conditions in which the rosiglitazone did not alter these parameters in untreated mice (Figures 2B, 2E, 11 
and 2F). In addition, rosiglitazone significantly reduced the increase in plasma corticosterone levels 12 
induced by treatment with NAC, without modify the baseline levels of this hormone in the circulation 13 
(Figure 2G). 14 
 15 
Rosiglitazone reduces adrenal overexpression of MC2R induced by the NAC treatment 16 
 We noted that mice treated with NAC increased the adrenal expression of both ACTH 17 
receptor (MC2R) (Figure 3A) and steroidogenic enzyme StAR (Figure 3A) in comparison to control 18 
mice. Rosiglitazone significantly reduced NAC-induced upregulation of MC2R expression without 19 
interfering with StAR expression (Figure 3A and 3B, respectively), under conditions where the 20 
baseline levels of these receptors remained unaltered (Figure 3). 21 
 22 
Rosiglitazone reduces hypercorticoidism induced by NAC treatment through PPARγ activation 23 
Treatment with NAC reduced PPARγ expression in adrenal glands compared to untreated mice. It is 24 
of interest note that rosiglitazone did not enhance the PPARγ RNAm expression in both untreated and 25 
NAC-treated mice (Figure 4A). Likewise, the pre-treatment with PPARγ antagonist GW9662 blocked 26 
 9 
the inhibitory properties of rosiglitazone on NAC-induced hypercorticoidism, indicating that PPARγ 1 
negatively regulates corticosterone production. Furthermore, the treatment with GW9662 did not alter 2 
NAC-induced upregulation in plasma corticosterone leve s in this model (Figure 4B). 3 
 4 
Figure 2: Rosiglitazone reduces adrenal hypertrophy and plasma corticosterone levels observed 5 
in NAC-treated mice. Mice were treated concomitantly with NAC (150 mg/kg, oral route) and 6 
rosiglitazone (0.5 mg/kg, i.p.) once daily for 5 consecutive days. Control animals were treated daily 7 
with rosiglitazone for 5 consecutive days.  Untreated animals received an equal amount of vehicle 8 
(DMSO 0.05 %, i.p.), and analyses were performed 24 hours after treatments. Representative 9 
photomicrographs of zona fasciculata of adrenal glands stained with Hematoxylin & Eosin of naive 10 
 10
mice (A), rosiglitazone treated mice (B), NAC treated mice (C) and NAC plus rosiglitazone treated 1 
mice (D). (E) Quantification of the mean area of z na fasciculata cells. (F) The ratio between adrenal 2 
and body weight. (G) Plasma quantification of corticosterone levels. Data are expressed as the mean ± 3 
SEM. +P<0.05 compared to control mice. ++P<0.01 compared to control mice. *P<0.05 compared to 4 
NAC-treated mice. ** P<0.01 compared to NAC-treated mice. Scale bar = 50 μm. NAC = N-5 
acetylcysteine. Rosi = Rosiglitazone. 6 
 7 
 8 
Figure 3: Rosiglitazone reduces MC2R expression but not StAR in the adrenals of NAC-treated 9 
mice. Mice were treated concomitantly with NAC (150 mg/kg, oral route) and rosiglitazone (0.5 10 
mg/kg, i.p.) once daily for 5 consecutive days. Contr l animals were treated daily with rosiglitazone 11 
for 5 consecutive days.  Untreated animals received an equal amount of vehicle (DMSO 0.05 %, i.p.), 12 
and analyses were performed 24 hours after treatments. MC2R (A) and StAR (B) gene expression in 13 
adrenals of mice measured by qPCR. Data are expressed as the mean ± SEM. +P<0.05 compared to 14 











Figure 4: Blockade of PPARγ  impaired rosiglitazone-mediated reduction of plasma 5 
corticosterone levels in NAC-treated mice. Mice were treated concomitantly with NAC (150 mg/kg, 6 
oral route), rosiglitazone (0.5 mg/kg, i.p.), and/or GW9662 (0.5 mg/kg, i.p.) once daily for 5 7 
consecutive days.  Untreated animals received an equal amount of vehicle (DMSO 0.1 %, i.p.), and 8 
analyses were performed 24 hours after treatments. (A) PPARγ gene expression in adrenals of mice 9 
measured by qPCR. (B) Plasma quantification of cortic s erone levels. Data are expressed as the 10 
mean ± SEM from. +P<0.05 compared to control mice. +++P<0.001 compared to control mice. 11 
*** P<0.001 compared to NAC-treated mice. #P<0.05 compared to NAC plus rosiglitazone-treated 12 




This study investigated the role of PPARγ on the NAC treatment-induced hypercorticoidism. 1 
We found that the antioxidant NAC increased plasma levels of corticosterone in mice even in a short 2 
time treatment. Furthermore, we showed that the PPARγ agonist rosiglitazone reversed the 3 
hypercorticoidism and the adrenal hypertrophy caused by NAC treatment. Rosiglitazone also 4 
decreased the local expression of MC2R. The reduction in plasma corticosterone levels provoked by 5 
rosiglitazone was blocked by GW9662, a PPARγ antagonist, regardless the level of PPARγ 6 
expression. Our findings indicate that lower expression of PPARγ in adrenals of NAC-treated mice 7 
might account for the hypercorticoidism observed in these animals, along with up-regulation of 8 
ACTH receptor expression. 9 
Currently, many people consume antioxidant supplements regularly to avoid developing 10 
diseases associated with aging [18,19]. Nevertheless, several clinical trials testing benefits and harms 11 
of dietary supplementation with antioxidants found that these drugs have been unable to show helpful 12 
effects and pointed that they seemed to induce an augmentation in all-cause mortality [20–23]. We 13 
previously demonstrated that the prolonged treatment with two different antioxidants, NAC and 14 
vitamin E, which act through distinct mechanisms of action increased plasma corticosterone levels in 15 
rats [10], however, the effects of acute use of these drugs on steroidogenesis are unknown. We 16 
performed here a treatment kinetics in Swiss-Webster mice and demonstrated that NAC rises the 17 
circulating levels of corticosterone after three consecutive days of treatment, remaining high at all 18 
subsequent times analyzed. Here, we noted that NAC treatment was able to induce the production of 19 
the primary stress hormone in an animal species other than the rat, suggesting that this phenomenon 20 
may occur in a larger spectrum of species, including human beings. Furthermore, we demonstrated in 21 
this work that even an acute treatment with NAC canincrease glucocorticoid production by mice, 22 
which makes the indiscriminate use of antioxidant die ary supplementation even more risky. 23 
It is currently known that ROS, including superoxide and hydrogen peroxide, generated by 24 
normal cell metabolism can act as intracellular signaling being crucial for the maintenance of cellular 25 
homeostasis [6,7,24]. In addition, exogenous antioxidants are able to reduce the expression and/or 26 
activity of endogenous antioxidant enzymes [25,26] by down-regulation of transcription factors 27 
 13
engaged in crosstalk for cytoprotection [10]. PPARγ is expressed in both murine and human 1 
adrenals[15,27,28], but also in cell lines[29], and its activation attenuated cortisol levels in patients 2 
with Cushing disease [30], as well as played a significa t role in conferring cytoprotection against 3 
endogenous oxidative stress [12–14]. Therefore, it could then be hypothesized that NAC could 4 
decreasing PPARγ expression and/or activation in adrenal glands, provoking an enhancement of the 5 
steroidogenic pathway. The fact that the rosiglitazone inhibited NAC-induced hypercorticoidism in 6 
parallel to a reduction of adrenal micro and macro hypertrophy, reinforce this hypothesis. Moreover, 7 
this idea is consistent with data showing that rosiglitazone treatment inhibited both adrenal 8 
hypertrophy and hypercorticoidism in diabetic animals [15]. 9 
We previously showed that antioxidant-induced hypercorticoidism occurred in parallel with 10 
an increase in the expression of the ACTH receptor MC2R and the steroidogenic enzyme StAR in the 11 
adrenals [10]. Here, we showed that rosiglitazone significantly inhibited NAC-induced 12 
overexpression of MC2R in adrenals, but not StAR. The reestablishment of MC2R expression by 13 
rosiglitazone may explain the reduction of plasma corti osterone levels induced by NAC, considering 14 
that the MC2R signaling pathway is essential to induce steroidogenesis and provoke subsequent 15 
adrenal hypertrophy and glucocorticoid secretion [31].  16 
We showed in this work that NAC treatment reduced the expression of PPARγ in adrenal 17 
glands, however, treatment with rosiglitazone did not i terfere with this effect of NAC. Despite that 18 
PPARγ activation usually induces its own gene transcription, including in adrenal glands [15,32], 19 
rosiglitazone could increase PPARγ activity without up-regulating protein amounts, esp cially 20 
considering the short period of drug administration [33]. Nevertheless,  Since rosiglitazone did not 21 
increase PPARγ expression in the adrenal glands of antioxidant-treated mice, one possible explanation 22 
would be that this thiazolidinedione could inhibit NAC-induced steroidogenesis through receptor-23 
independent effects [34,35]. 24 
 To understand whether a decrease in the circulating levels of corticosterone by rosiglitazone 25 
is PPARγ-dependent in NAC-treated mice, we performed experim nts using a PPARγ antagonist 26 
GW9662. Here, we showed that the effect of rosiglitazone in reducing NAC treatment-induced 27 
 14
hypercorticoidism was completely abolished in mice tr ated simultaneously with GW9662, 1 
suggesting that this effect is dependent on the PPARγ activation by rosiglitazone. Although we did not 2 
observe that rosiglitazone increased the expression of PPARγ in the adrenal glands of NAC-treated 3 
mice, the fact that the PPARγ antagonist prevents the effect of rosiglitazone on NAC-induced 4 
hypercorticoidism indicates that rosiglitazone is acting by activating this receptor. In addition, thefact 5 
that the lower expression of PPARγ induced by NAC is related directly to the higher expression of 6 
MC2R in the adrenals is in line with what was shown by us earlier in diabetic rats [15]. Thus, these 7 
findings also suggest that in adrenal glands, PPARγ is a transcription factor that induces MC2R gene 8 
transrepression. 9 
In summary, our results indicate that NAC-induced hypercorticoidism in mice is related to the 10 
loss of PPARγ cytoprotective capacity.  This effect seems be caused by a reduced PPARγ mRNA 11 
transcription, which could lead to a subsequent transactivation of the ACTH receptor (MC2R). In 12 
addition, the activation of PPARγ with rosiglitazone normalizes the dysregulation in adrenal 13 
steroidogenesis induced by NAC treatment. 14 
 15 
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• Oral supplementation with N-acetyl-cysteine (NAC) induces 
hypercorticoidism.  
 
• NAC induces hypercorticoidism by reduction of PPARγ 
expression in adrenals. 
 
 
• PPARγ activation reduces NAC-induced ACTH receptor 
expression in adrenals. 
 
